Isolated limb perfusion with TNF-alpha and melphalan for distal parts of the limb in soft tissue sarcoma patients

Jan Deroose, AN Geel, Pim Burger, Lex Eggermont, Kees Verhoef

Research output: Contribution to journalArticleAcademicpeer-review

15 Citations (Scopus)


Background Approximately 10% of soft tissue sarcomas (STS) occur in the most distal parts of the extremities. The standard therapy is local excision with adjuvant radiotherapy, but achieving wide resection margins might be difficult in the distal parts of the limb. Tumor necrosis factor-alpha (TNF) and melphalan-based isolated limb perfusion (TM-ILP) is effective in locally advanced STS of the extremities. We report the results of TM-ILP for STS in the most distal parts of the limb. Methods: Between 1991 and 2009, 34 ILPs were performed in patients with irresectable STS of the wrist, hand, ankle, or foot. Disease was unifocal in 21 (62%) patients. Results: Overall response rate was 71% (n 24). After a median follow-up of 34 (range 1-143) months the local recurrence rate was 32%. Amputation was unavoidable in four patients (13%), four other patients (13%) underwent a partial amputation of the hand or foot. Conclusion: With a limb salvage rate of 87%, TM-ILP is an effective treatment modality in patients with distal STS. In all patients with an indication for amputation surgery due to an STS in the distal part of the limb, TM-ILP should be considered. J. Surg. Oncol. 2012; 105: 563-569. (C) 2011 Wiley Periodicals, Inc.
Original languageUndefined/Unknown
Pages (from-to)563-569
Number of pages7
JournalJournal of Surgical Oncology
Issue number6
Publication statusPublished - 2012

Cite this